Advertisement

The Effectiveness of Antidepressants Today

  • Tullio GiraldiEmail author
Chapter
  • 1.2k Downloads

Abstract

In this chapter we discuss tricyclic antidepressants, which were initially used with remarkable success on the limited number of patients suffering from serious endogenous depression. The therapeutic action obtained was accompanied by considerable side effects . This encouraged the search for effective antidepressants that would be better tolerated by the patients, leading to the use of selective serotonin reuptake inhibitors These compounds rapidly encountered the favour of psychiatrists, and Prozac , the progenitor of this class, was prescribed between 1987 and 2002 to 40 million Americans with sales of 22 billion dollars. Subsequent serious investigations revealed that the clinical trials given to the regulatory agencies used unreal and irrelevant criteria of effectiveness; in the real world, few patients responded to the treatment at all, and for mild depression the response was equal to that of a placebo

References

  1. Abraham, J., & Davis, C. (2009). Drug evaluation and the permissive principle continuities and contradictions between standards and practices in antidepressant regulation. Social Studies of Science, 39(4), 569–598.CrossRefPubMedGoogle Scholar
  2. Adams, C. P., & Brantner, V. V. (2006). Estimating the cost of new drug development: Is it really $802 Million? Health Affairs, 25(2), 420–429.CrossRefPubMedGoogle Scholar
  3. Adams, C. P., & Brantner, V. V. (2010). Spending on new drug development. Health Economy, 19(2), 130–141.CrossRefGoogle Scholar
  4. Baker, C. B., Johnsrud, M. T., Crismon, M. L., et al. (2003). Quantitative analysis of sponsorship bias in economic studies of antidepressants. British Journal of Psychiatry, 183, 498–506.CrossRefPubMedGoogle Scholar
  5. Beck, J. S. (1995). Cognitive therapy: Basics and beyond. New York: The Guilford Press.Google Scholar
  6. Bracken, M. B. (2013). Risk, chance and causation. Investigating the origins and treatment of diseases. New Haven: Yale University Press.CrossRefGoogle Scholar
  7. Brunton, L., Lazo, J., & Parker, K. (2005). Goodman & Gilman’s, The pharmacological basis of therapeutics (11th ed.). New York: McGraw-Hill Medical.Google Scholar
  8. Cochrane. (2016). Cochrane. Trusted evidence. Informed decisions. Better health. n.d. http://www.cochrane.org/about-us Accessed 30 May 2016.
  9. Cosgrove, L., Krimsky, S., Vijayaraghavan, M., et al. (2006). Financial ties between DSM-IV panel members and the pharmaceutical industry. Psychotherapy and Psychosomatics, 75(3), 154–160.CrossRefPubMedGoogle Scholar
  10. Cosgrove, L., Krimsky, S., Wheeler, E. E., et al. (2014). Tripartite conflicts of interest and high Stakes Patent Extensions in the DSM-5. Psychotherapy and Psychosomatics, 83(2), 106–113.CrossRefPubMedGoogle Scholar
  11. Dokoupil, T. (2010). America’s long love affair with anti-anxiety drugs. http://www.newsweek.com/americas-long-love-affair-anti-anxiety-drugs-77967. Accessed 25 March 2015.
  12. Elmore, J. G., & Feinstein, A. R. (1994). Joseph Goldberger: An unsung hero of American clinical epidemiology. Annals of Internal Medicine, 121(5), 372–375.CrossRefPubMedGoogle Scholar
  13. FDA. (1997). Guidance for industry. Guidance for the clinical evaluation of antidepressant drugs. Center for Drug Evaluation and Research. U.S. Department of Health and Human Services, Food and Drug Administration. U.S. Food and Drug Administration. Protecting and promoting your health. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071299.pdf. Accessed 20 March 2014.
  14. FDA. (2015). List of antidepressants drugs with medication guides http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM161647.pdf. Accessed 2 February 2015.
  15. Fountoulakis, K. N., Veroniki, A. A., Siamouli, M. et al. (2013). No role for initial severity on the efficacy of antidepressants: Results of a multi-meta-analysis. Annals of General Psychiatry, 12(1): 26–36. doi:  10.1186/1744-859X-12-26.
  16. Fournier, J. C., DeRubeis, R. J., Hollon, S. D., et al. (2010). Antidepressant drug effects and depression severity. A patient-level meta-analysis. The Journal of American Medical Association, 303(1), 47–53.CrossRefGoogle Scholar
  17. Fung, M., Thornton, A., Mybeck, K., et al. (2001). Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets 1960 to 1999. Therapeutic Innovation & Regulatory Science, 35(1), 293–317.Google Scholar
  18. Gaynes, B. N., Warden, D., Trivedi, M. H., et al. (2009). What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatric Services, 60(11), 1439–1445.CrossRefPubMedGoogle Scholar
  19. Ghaemi, S. N. (2008). Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression. Bipolar Disorders, 10(8), 957–968.CrossRefPubMedGoogle Scholar
  20. Goetzsche, P. (2015). Deadly psychiatry and organized denial. København: People’s Press.Google Scholar
  21. Goozner, M. (2004). The $800 million pill. The truth behind the cost of new drugs. Oakland: University of California Press.Google Scholar
  22. Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 56–62.CrossRefPubMedPubMedCentralGoogle Scholar
  23. Hamilton, M. (1967). Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology, 6(4), 278–296.CrossRefPubMedGoogle Scholar
  24. Healy, D. (1997). The antidepressant era. Cambridge: Harvard University Press.Google Scholar
  25. Huedo-Medina, T. B., Johnson, B. T., & Kirsch, I. (2012). Kirsch et al.’s (2008) calculations are correct: Reconsidering Fountoulakis & Moller’s re-analysis of the Kirsch data. International Journal of Neuropsychopharmacology, 15(8), 1193–1198.CrossRefPubMedGoogle Scholar
  26. Insel, T. (2009). Beyond efficacy: The STAR*D Trial. National Institute of Mental Health (NIMH). http://www.nimh.nih.gov/about/director/bio/publications/beyond-efficacy-the-star-d-trial.shtml. Accessed 24 March 2014.
  27. Insel, T. (2014). Director’s Blog: A new approach to clinical trials. National Institute of Mental Health. Retrieved February 1, 2015, from http://www.nimh.nih.gov/about/director/2014/a-new-approach-to-clinical-trials.shtml.
  28. Khan, A., Leventhal, R. M., Khan, S. R., et al. (2002). Severity of depression and response to antidepressants and placebo: An analysis of the food and drug administration database. Journal of Clinical Psychopharmacology, 22(1), 40–45.CrossRefPubMedGoogle Scholar
  29. Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008). Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine, 5(2), e45. doi:  10.1371/journal.pmed.0050045 .
  30. Kirsch, I., & Sapirstein, G. (1998). Listening to prozac but hearing placebo: A meta-analysis of antidepressant medication. Prevention & Treatment, 1(2). http://dx.doi.org/10.1037/1522-3736.1.1.12a.
  31. Leucht, C., Huhn, M., & Leucht, S. (2012). Amitriptyline versus placebo for major depressive disorder. Cochrane Database of Systematic Reviews, (12). doi:  10.1002/14651858.
  32. Leucht, S., Fennema, H., Engel, R., et al. (2013). What does the HAMD means? Journal of Affective Disorders, 148(2–3), 243–248.CrossRefPubMedGoogle Scholar
  33. Melander, H., Ahlqvist-Rastad, J., Meijer, G., et al. (2003). Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: Review of studies in new drug applications. British Medical Journal, 326(7400), 1171–1173.CrossRefPubMedPubMedCentralGoogle Scholar
  34. Moncrieff, J., & Kirsch, I. (2005). Efficacy of antidepressants in adults. Britsh Medical Journal, 331(7509), 155–159.CrossRefGoogle Scholar
  35. Mullin, R. (2014). Tufts study finds big rise in cost of drug development. Chemical & Engineering News, 92(47), p. 6. Retrieved February 1, 2015, from http://cen.acs.org/articles/92/i47/Tufts-Study-Finds-Big-Rise.html?type=paidArticleContent.
  36. Murrough, J. W., & Charney, D. S. (2012). Is there anything really novel on the antidepressant horizon? Current Psychiatry Reports, 14(6), 643–649.CrossRefPubMedPubMedCentralGoogle Scholar
  37. National Institute for Health and Care Excellence (NICE). (2004). Depression: Management of depression in primary and secondary care NICE guidelines [CG23]. Retrieved May 30, 2016, from https://www.nice.org.uk/guidance/cg23.
  38. National Institute for Health and Care Excellence (NICE). (2009). Depression in adults: The treatment and management of depression in adults. Retrieved April 12, 2015, from https://www.nice.org.uk/guidance/cg90.
  39. NIMH. (2006). Sequenced treatment alternatives to relieve depression (STAR*D). ClinicalTrials.gov, http://www.clinicaltrials.gov/ct/show/NCT00021528?order=1. Accessed March 20, 2014.
  40. Penn, E., & Tracy, D. K. (2012). The drug don’t work? Antidepressants and the current and future pharmacological management of depression. Therapeutic Advances in Psychopharmacology, 2(5), 179–188.CrossRefPubMedPubMedCentralGoogle Scholar
  41. Rush, A. J., First, M. B., & Blacker, D. (2000). Handbook of psychiatric measures. Washington, DC: American Psychiatric Press.Google Scholar
  42. Rush, A. J., Warden, D., Wisniewski, S. R., et al. (2009). STAR*D. Revising Conventional Wisdom. CNS Drugs, 23(8), 627–647.PubMedGoogle Scholar
  43. Shulman, K. I., Herrmann, N., & Walker, S. E. (2013). Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs, 27(10), 789–797.CrossRefPubMedGoogle Scholar
  44. Sinyor, M., Schaffee, A., & Levitt, A. (2010). The sequenced treatment alternatives to relieve depression (STAR*D) trial: A review. La Revue Canadienne de Psychiatrie, 55(3), 126–137.Google Scholar
  45. Tone, A. (2009). The age of anxiety: A history of America’s turbulent affair with tranquilizers. New York: Basic Books.Google Scholar
  46. Turner, E. H., Matthews, A. M., Linardatos, E., et al. (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine, 358, 252–260.CrossRefPubMedGoogle Scholar
  47. Vöhringer, P. A., & Ghaemi, S. N. (2011). Solving the antidepressant efficacy question: Effect sizes in major depressive disorder. Clinical Therapeutics, 33(12), B49–B61.CrossRefPubMedPubMedCentralGoogle Scholar
  48. Warden, D., Rush, A. J., Trivedi, M. H., et al. (2007). The STAR*D project results: A comprehensive review of findings. Current Psychiatry Reports, 9(6), 449–459.CrossRefPubMedGoogle Scholar
  49. Wong, D. T., Perry, K. W., & Bymaster, F. P. (2005). The discovery of fluoxetine hydrochloride (Prozac). Nature Reviews Drug Discovery, 4, 764–774.PubMedGoogle Scholar

Copyright information

© The Author(s) 2017

Authors and Affiliations

  1. 1.University of TriesteTriesteItaly

Personalised recommendations